BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 37265006)

  • 1. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
    Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
    Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [
    Zhang P; Zhao Z; Zhang L; Wu W; Xu Y; Pan D; Wang F; Yang M
    Nucl Med Biol; 2019; 74-75():19-24. PubMed ID: 31450071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
    Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the Theranostic Potential of Exendin 4 by Reducing the Renal Radioactivity through Brush Border Membrane Enzyme-Mediated Degradation.
    Zhang M; Jacobson O; Kiesewetter DO; Ma Y; Wang Z; Lang L; Tang L; Kang F; Deng H; Yang W; Niu G; Wang J; Chen X
    Bioconjug Chem; 2019 Jun; 30(6):1745-1753. PubMed ID: 31181890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
    Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
    Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
    Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
    J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic Tracers.
    Rylova SN; Waser B; Del Pozzo L; Tönnesmann R; Mansi R; Meyer PT; Reubi JC; Maecke HR
    J Nucl Med; 2016 Aug; 57(8):1282-8. PubMed ID: 27127218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an
    Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
    Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
    Wild D; Antwi K; Fani M; Christ ER
    J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation of [
    Guleria M; Das T; Amirdhanayagam J; Sarma HD; Dash A
    Nucl Med Biol; 2019; 78-79():31-40. PubMed ID: 31731177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.
    Wild D; Wicki A; Mansi R; Béhé M; Keil B; Bernhardt P; Christofori G; Ell PJ; Mäcke HR
    J Nucl Med; 2010 Jul; 51(7):1059-67. PubMed ID: 20595511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioiodinated Exendin-4 Is Superior to the Radiometal-Labelled Glucagon-Like Peptide-1 Receptor Probes Overcoming Their High Kidney Uptake.
    Läppchen T; Tönnesmann R; Eersels J; Meyer PT; Maecke HR; Rylova SN
    PLoS One; 2017; 12(1):e0170435. PubMed ID: 28103285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Activity Relationships and Pharmacokinetics of
    Iikuni S; Ohara T; Watanabe H; Ono M
    Mol Pharm; 2022 Aug; 19(8):2832-2839. PubMed ID: 35757958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for Clinical GLP-1 Receptor PET/CT Imaging with [
    Tokgöz S; Boss M; Prasad S; Shah P; Laverman P; van Riel M; Gotthardt M
    Methods Mol Biol; 2023; 2592():143-153. PubMed ID: 36507990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary evaluation of [18F]AlF-NOTA-MAL-Cys39-exendin-4 in insulinoma with PET.
    Xu Q; Zhu C; Xu Y; Pan D; Liu P; Yang R; Wang L; Chen F; Sun X; Luo S; Yang M
    J Drug Target; 2015; 23(9):813-20. PubMed ID: 25758750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
    Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
    Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical evaluation of [(68)Ga]Ga-DO3A-VS-Cys(40)-Exendin-4 for imaging of insulinoma.
    Selvaraju RK; Velikyan I; Asplund V; Johansson L; Wu Z; Todorov I; Shively J; Kandeel F; Eriksson B; Korsgren O; Eriksson O
    Nucl Med Biol; 2014 Jul; 41(6):471-6. PubMed ID: 24857864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor expression after myocardial infarction: Imaging study using
    Ståhle M; Kytö V; Kiugel M; Liljenbäck H; Metsälä O; Käkelä M; Li XG; Oikonen V; Saukko P; Nuutila P; Knuuti J; Roivainen A; Saraste A
    J Nucl Cardiol; 2020 Dec; 27(6):2386-2397. PubMed ID: 30547299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [
    Migliari S; Sammartano A; Boss M; Gotthardt M; Scarlattei M; Baldari G; Silva C; Bonadonna RC; Ruffini L
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056858
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of a New Folate-Derived Ga-68-Based PET Imaging Agent.
    Brand C; Longo VA; Groaning M; Weber WA; Reiner T
    Mol Imaging Biol; 2017 Oct; 19(5):754-761. PubMed ID: 28194631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.